Company Overview and News


Add GERN
to your dashboard

Headline News

Your Daily Pharma Scoop: Geron's Fate, Celldex Commences Mid-Stage Study, Novartis's Tasigna

12h seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (141-0)

Geron Short Interest Is Dropping Steadily

2017-11-17 seekingalpha
There has been a significant and steady drop in Geron (GERN) Short Interest over the past five months. (41-0)

3 Things In Biotech You Should Learn Today: November 16, 2017

2017-11-16 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (41-0)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

2017-11-02 zacks
Geron Corporation (GERN - Free Report) reported a loss of 4 cents per share in the third quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of 5 cents. In the year-ago quarter, the company had recorded a loss of 2 cents. (116-2)

Geron Corporation's (GERN) CEO Dr. John Scarlett on Q3 2017 Results - Earnings Call Transcript

2017-11-02 seekingalpha
Good day, ladies and gentlemen and welcome to our Q3 2017 Geron Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] (41-2)

Finally, Geron IMerges With Some Movement In MDS

2017-11-01 seekingalpha
Geron Corporation has had a quiet year as shareholders await a decision from their big partner on continuation of their collaboration. (53-0)

Geron Corporation to Host Earnings Call

2017-11-01 accesswire
(41-0)

Your Daily Pharma Scoop: Gilead In NASH, Geron Gets A Boost, AstraZeneca's Oncology Portfolio

2017-11-01 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (498-1)

Geron (GERN) in Focus: Stock Moves 9.2% Higher

2017-11-01 zacks
Geron Corporation (GERN - Free Report) was a big mover last session, as the company saw its shares rise over 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.03–$2.32 in the past one-month time frame, witnessed a sharp increase yesterday. (263-1)

3 Things, November 1, 2017: Geron On Fast Track, AstraZeneca's New Approval, Novartis Tackles DLBCL

2017-11-01 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (106-1)

Can This FDA Approval Keep Lifting Geron?

2017-10-31 247wallst
Geron Corp. (NASDAQ: GERN) is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day. The reason for Geron’s move is a crucial U.S. Food and Drug Administration (FDA) approval that came at just the right time for this stock. (46-2)

What's in the Cards for Geron (GERN) this Earnings Season?

2017-10-27 zacks
Geron Corporation (GERN - Free Report) is scheduled to report third-quarter 2017 results on Nov 1 after market closes. (86-0)

3 Things In Biotech You Should Learn Today: September 26, 2017

2017-09-26 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (197-2)

Stock Research Report

Geron Corporation is a biopharmaceutical company that currently supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen. Early clinical data, including molecular responses in essential thrombocythemia, or ET, and remission responses, including reversal of bone marrow fibrosis, in myelofibrosis, or MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

In November 2014, Geron entered into a collaboration and license agreement, or the Collaboration Agreement, pursuant to which the company granted Janssen the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. The Collaboration Agreement became effective in December 2014 and the company received $35 million from Janssen ...

Click for full article
CUSIP: 374163103